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Abstract  
Objectives 
To compare visual and anatomical outcomes between eyes treated with fluocinolone 
acetonide (FAc) 190 µg intravitreal implant for clinically significant chronic diabetic 
macular oedema (DMO) and fellow eyes not treated with FAc implant using data 
from the Iluvien Clinical Evidence study in the UK (ICE-UK) study. 
Methods 
In this retrospective cohort study, data on people attending hospital eye services 
and treated with FAc implant between 1 April 2013 and 15 April 2015 were 
collected. Changes in visual acuity (VA), central foveal thickness (CFT) and intraocular 
pressure (IOP) were compared between study eyes (intervention) and fellow eyes. 
Results 
208 people were selected. Mean age was 68.1 years and 62% were male. Mean 
change in VA was -0.09 LogMAR units for study eyes and 0.04 LogMAR units for 
fellow eyes at 12 months post implant (p<0.001). Over the same period, ≥5 letter, 
≥10 letter and ≥15 letter improvements in ETDRS score were achieved by more FAc 
treated eyes than by fellow eyes (41% versus 23%, p<0.001; 28% versus 11%, 
p<0.001; and 18% versus 4%, p<0.001 at 12 months, respectively). Differences in the 
mean change in CFT (-113 µm versus -13 µm, p<0.001) and IOP (3.2 mmHg versus -
0.2 mmHg, p<0.001) were also observed between study and fellow eyes at 12 
months.  
Conclusion 
Visual acuity improved in study eyes and worsened in fellow eyes over the 12 
months following FAc implant. Over the same period, study eyes showed a larger 
improvement in central foveal thickness. Intraocular pressure worsened in study 
eyes only. Change in visual acuity, central foveal thickness and intraocular pressure 
between FAc implant and the end of the 12 months follow-up period differed 
significantly between study and fellow eyes.
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Introduction 
Diabetic retinopathy is amongst the most feared of the microvascular complications 
of type 1 and type 2 diabetes mellitus and was until very recently the most common 
cause of visual loss and blindness in working-aged people.1,2 Up to 2010, it was 
estimated that 35% of people with diabetes worldwide had diabetic retinopathy.3 As 
diabetic retinopathy progresses, microvascular changes in the retina can lead to 
increased permeability, with leakage causing the accumulation of fluid in the 
macular. The global prevalence of diabetic macular oedema (DMO) in people with 
diabetes has been estimated as 7%3 and the condition is the major cause of vision 
loss in the diabetic population.4 
Several types of therapy are licensed for use in DMO. The Early Treatment Diabetic 
Retinopathy Study (ETDRS) showed that focal photocoagulation can lead to a 
reduced loss of vision in people with clinically significant DMO.5 Subsequently, data 
from several landmark trials have shown that anti-VEGF therapies can improve vision 
in people with DMO,6–9 and anti-VEGF therapy has become the treatment of choice 
for the management of DMO. Nevertheless, anti-VEGF therapies are not effective in 
all people.10 Dong and colleagues suggest that several cytokines associated with 
inflammation and angiogenesis contribute to the pathogenesis of diabetic 
retinopathy.11 Therefore, a multifactorial approach to the management of diabetic 
retinopathy could be beneficial.11 Intravitreal corticosteroids have been shown to be 
effective in improving visual acuity in DMO12–14 and reduce not only the expression 
of the VEGF gene but also suppress other inflammatory mediators. Intravitreal 
steroids are therefore potentially useful second-line agents in the management of 
DMO. 
Fluocinolone acetonide (FAc) 190 µg intravitreal implant is licensed in 17 European 
countries for the treatment of visual impairment associated with chronic DMO 
considered insufficiently responsive to available therapies. Two separate randomised 
clinical trials, Fluocinolone Acetonide in Diabetic Macular Oedema (FAME) A and 
FAME B, have been conducted to study the clinical effectiveness of FAc intravitreal 
implant in DMO.13,15,16 These studies recruited people with DMO previously treated 
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with retinal laser therapy, and the combined results of the two trials indicated that 
the FAc intravitreal implant provided visual benefit for up to three years.13,12 Due to 
its long duration of action, the FAc intravitreal implant needs to be administered less 
frequently compared with anti-VEGF and other steroid therapies for DMO.17 
However, intravitreal corticosteroids have been shown to be associated with side 
effects including steroid-induced cataracts and raised intraocular pressure (IOP).12–14 
The UK National Institute of Health and Care Excellence (NICE) currently 
recommends that FAc intravitreal implant be used only in eyes with pseudophakic 
lenses where the DMO has been insufficiently responsive to available therapies.18 
The aim of the Iluvien Clinical Evidence study in the United Kingdom (ICE-UK) was to 
assess the real-world effectiveness of FAc intravitreal implant for chronic DMO in 
routine clinical practice. Changes in visual acuity, central foveal thickness (CFT) and 
IOP were compared between FAc treated and fellow eyes post implant. Whilst 
randomised trials of DMO-related treatments provide a direct comparison between 
FAc treated and untreated subjects, here we compared study eyes (first eyes treated 
with FAc implant) and fellow eyes (the patient’s eye not treated with FAc implant, 
but which may have other standard care) in the same subject since this provides a 
natural experiment whereby the reference (control) eye is exposed to exactly the 
same physiological milieu. The low daily release of FAc from the intravitreal implant 
provides systemic FAc levels that are undetectable in the systemic circulation;19 
therefore the effect of the FAc implant in the study eye affecting the disease in the 
fellow eye is low. However, unlike randomised controlled trials, the decision as to 
which eye to treat is likely to be based on a clinical decision. Nevertheless the 
premise of the study was based on the assumption that there was homogeneity 
between study and fellow eyes.  
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Methods 
Data Source 
This study used a retrospective cohort design. The data source has been described 
previously.20 Briefly, data were extracted from patient medical records for a 
representative cohort of patients registered at 13 participating UK hospitals. Data 
were pseudonymised and combined into a single dataset. Data included 
demographics, medical history, implant data, and data from multi-disciplinary and 
medication reviews at several time points within a designated period.  
 
Ethical approval 
The lead clinician and Caldicott Guardian at each centre gave written approval for 
extraction of anonymised data. The study protocol was approved by the head of 
research governance at the lead clinical centre. This study was conducted in 
accordance with the Declaration of Helsinki and the UK Data Protection Act. 
 
Subjects 
People with type 1 or type 2 diabetes treated with FAc intravitreal implant for DMO 
in at least one eye were included in the study. In order to allow for sufficient follow-
up, it was required that the implant be inserted between 1 April 2013 and 15 April 
2015 at a participating site as part of the patient’s routine care. The period of 
observation ended on 15 April 2016. A minimum history of 12 months prior to 
implant was also required, providing information that is not available in randomised 
controlled trials. People with a history of participating in any interventional study for 
DMO or with insufficient follow-up were excluded. Reasons for insufficient follow-up 
included: non-attendance at the clinic and last appointment missing the last 
appointment post index. Study eyes were defined as the first eye to be treated with  
FAc implant. Fellow eyes were defined as the eye that received no FAc implant; 
these could receive other DMO treatments as deemed clinically necessary in routine 
practice. People whose fellow eye was treated with FAc intravitreal implant within 
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12 months of the study eye’s first treatment were censored at the time of implant, 
with all remaining subjects followed for 12 months post implant. The index date was 
defined as the date of the first recorded FAc intravitreal implant into the study eye.  
  
Outcomes 
Change in visual acuity, CFT and IOP were investigated at 3, 6 and 12 months post 
index date in study and fellow eyes. Visual acuity was measured using one of: Early 
Treatment of Diabetic Retinopathy Study (ETDRS) scores, Snellen fractions or 
LogMAR scores. All Snellen fractions were converted to approximate ETDRS scores 
for analysis using the following formula derived by Gregori and colleagues: 
approximate ETDRS = 85 + 50 x log (Snellen fraction). All approximate ETDRS scores 
were rounded to the nearest letter.21 Snellen fractions were converted to LogMAR 
scores using the following formula: -1 x log (Snellen fraction).21 These formulae were 
rearranged to convert between LogMAR and ETDRS. People who could only detect 
movement, detect light or count fingers were allocated to 2.3 on the LogMAR scale, 
the value attributed to people who can count fingers. As this was an observational 
study, there was no restriction on the optical coherence tomography (OCT) machine 
type used to measure retinal thickness. 
 
Statistical analysis 
Results were compared between study eyes and fellow eyes. Baseline characteristics 
were displayed for study and fellow eyes overall and by subgroup based on the 
difference in the mean change in visual acuity between study and fellow eyes at 12 
months post implant (> and ≤-0.12 LogMAR units). Baseline characteristics were 
compared using the paired t-test or Wilcoxon signed rank test for continuous 
variables, depending on their distribution. Changes in visual acuity, CFT and IOP were 
compared between study and fellow eyes using the Wilcoxon signed rank test. 
Categorical variables were compared using McNemar’s test. Due to the 
observational nature of this study, people did not visit the clinic at set times prior to 
and following insertion of the FAc intravitreal implant. Therefore last observation 
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carried forward prior to and after implant was implemented in order to impute 
missing values.22  
Mean change in the four study outcomes on each day following baseline and mean 
values on each day in the 12 months prior and post index date were calculated using 
a dataset where missing values had been imputed using linear interpolation.22 As 
linear interpolation was not suitable following the last observed value or prior to the 
first observed value, nearest observation carried forward and backward was used to 
impute the remaining missing values.  
Generalised linear mixed multinomial modelling with a random intercept at subject 
level and a generalised logit link function was conducted. The dependent variable 
was change in visual acuity categorised as ≥5 letter improvement, between -4 and +4 
letter change (i.e. stable visual acuity) and ≥5 letter worsening. The following 
variables were added as fixed effects: age, baseline visual acuity (LogMAR units), 
insulin treatment, sex, FAc implant, lens status, number of prior anti-VEGF injections, 
prior IOP-lowering therapy, number of prior laser therapies, number of prior steroid 
injections (triamcinolone or dexamethasone) and prior vitrectomy. All statistical 
analyses were carried out using IBM SPSS statistics version 20.  
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Results 
Data were collected on 311 people, of whom 208 people contributing 208 study eyes 
and 208 fellow eyes were eligible for inclusion in the study cohort. The number of 
study subjects excluded has been described previously.20 
 
Patient characteristics 
Of the 208 people treated with FAc intravitreal implant in the study eye, 128 (62%) 
were male. Mean age was 68.1 years (Table 1). 176 (85%) people had type 2 
diabetes. Median (IQR) duration of diabetes was 18.0 (11.0–27.0) years. For 137 
(70%) people, vision was worse in the study eye. 
185 (89%) study eyes and 111 (53%) fellow eyes had a pseudophakic lens (p<0.001). 
At the time of implant, median visual acuity was worse in the study eye than in the 
fellow eye (median 0.69, IQR 0.49–1.00 LogMAR units versus 0.40, 0.19–0.80 
LogMAR units, p<0.001). Mean (standard deviation, SD) CFT was 483 (189) µm for 
study eyes and 371 (176) µm for fellow eyes (p<0.001). Study eyes had a history of 
receiving more anti-VEGF (p<0.001), steroid (p<0.001) and macular laser treatments 
(p=0.028) when compared with fellow eyes. IOP at baseline was similar in study and 
fellow eyes (median 15 versus 15 mmHg, p=0.236) and there was no significant 
difference in the number of study and fellow eyes that had been previously treated 
with IOP-lowering therapy (20% versus 16%, p=0.143). The percentage of patients 
receiving the FAc implant in a pseudophakic eye who had a phakic lens in their fellow 
eye was 37% for those receiving the FAc implant in their worse-seeing eye and 31% 
in those receiving the FAc implant in the study eye with the same or better visual 
acuity. Baseline characteristics by subgroup defined by difference in mean change in 
visual acuity between study eye and fellow eye at 12 months are displayed in 
Supplementary Table 1. 
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Other intraocular interventions 
The number of eyes treated with anti-VEGF post FAc implant in the study eye were: 
5% of study eyes versus 18% of fellow eyes between 0 and 3 months, 9% of study 
eyes versus 20% of fellow eyes between 3 to 6 months and 18% of study eyes versus 
24% of fellow eyes between 6 and 12 months (Table 2). The number of eyes treated 
with steroids (other than FAc) post FAc implant in the study eye were: 2% of study 
eyes versus 1% of fellow eyes between 0 and 3 months, 1% of study eyes versus 1% 
of fellow eyes between 3 and 6 months and 5% of study eyes versus 1% of fellow 
eyes between 6 to 12 months. The corresponding figures for macular laser therapy 
were 2% of study eyes versus 2% of fellow eyes, 3% of study eyes versus 2% of fellow 
eyes and 5% of study eyes versus 4% of fellow eyes at 0 to 3 months, 3 to 6 months 
and 6 to 12 months, respectively. 
23 study eyes (11%) had a phakic (natural) lens at baseline. A pseudophakic lens 
status or a cataract operation was recorded in 15 eligible phakic eyes (68%) between 
0 and 3 months post implant (including 11 cataract operations performed on day of 
FAc implant) and one eye (14%) between 3 and 6 months post implant. At the time 
of FAc implant in the study eye, 97 (47%) fellow eyes had a phakic lens. 10, 3 and 4 
eligible phakic eyes received a cataract operation or a change in lens status to 
pseudophakic at 0 to 3 months, 3 to 6 months and 6 to 12 months post implant. 
 
Change in visual acuity 
For the study eye, mean visual acuity was better in the 12 months following FAc 
implant when compared with the 12 months preceding implant (0.73 LogMAR units 
at -12 months, 0.76 LogMAR units immediately prior to implant and 0.67 LogMAR 
units at +12 months, Figure 1). Visual acuity in study eyes improved over the first 
four months of study follow-up (mean change -0.10 LogMAR units). Improvements in 
visual acuity decreased slightly between 4 and 12 months and mean change in visual 
acuity was -0.09 LogMAR units at 12 months post FAc implantation (Figure 2). For 
the fellow eye, mean visual acuity improved prior to index date (0.54 LogMAR units 
four months prior to implant to 0.5 LogMAR units at FAc implant) but then gradually 
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worsened over the 12 month follow-up period post implant (0.54 LogMAR units at 
12 months). Change in visual acuity was significantly different in study eyes and 
fellow eyes at 3 months (mean -0.08 versus -0.02 LogMAR units, respectively, 
p=0.008), 6 months (-0.11 versus 0.03 LogMAR units, respectively, p<0.001) and 12 
months post implant (-0.09 versus 0.04, respectively, p<0.001, Supplementary Table 
2). 
A ≥5 letter improvement in ETDRS score was achieved by more study eyes than 
fellow eyes at each follow-up time point (44% versus 22%, p<0.001, at 3 months; 
44% versus 30%, p=0.002, at 6 months; 41% versus 23%, p<0.001, at 12 months post 
implant, Figure 3). More study eyes also achieved a ≥10 letter improvement at 3 
months (26% versus 12%, p<0.001), 6 months (30% versus 10%, p<0.001) and 12 
months (28% versus 11%, p<0.001) post index date. For a ≥15 letter improvement in 
ETDRS the corresponding figures for study eyes and fellow eyes were 14% versus 7%, 
p=0.012 at 3 months; 16% versus 4%, p<0.001 at 6 months; and 18% versus 4%, 
p<0.001 at 12 months, respectively. At 6 and 12 months post FAc implant, fewer 
study eyes exhibited a worsening in visual acuity of ≥5, ≥10 and ≥15 letters 
compared with fellow eyes. However, this only achieved statistical significance for a 
≥10 letter worsening in ETDRS letter score at 6 months (10% of study eyes versus 
19% of fellow eyes, p=0.014).  
Results from the generalised linear mixed multinomial modelling showed that the 
study eyes were more likely to achieve a ≥5 letter gain in visual acuity and this result 
was significant at three months (exponential of the coefficient 2.09, 95% CI 1.13–
3.88, p=0.019) post implant (Table 3). Study eyes were not significantly more or less 
likely to have a worsening of ≥5 letters in visual acuity at 3, 6 and 12 months post 
implant. 
 
Change in central foveal thickness 
In the study eye, CFT fluctuated from 468 µm at -12 months to 445 µm at -4 months 
before increasing to 471 µm immediately prior to implant (Figure 1). Mean CFT then 
decreased gradually post implant from 407 µm immediately following implant to 358 
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µm at the end of the 12 months follow-up. For the fellow eye, there was little 
change in mean CFT in the 12 months before and after implant (CFT 345 µm, 343 µm 
and 330 µm at -12 months, index date and +12 months, respectively). A difference in 
the change in CFT was observed between study and fellow eyes between index date 
and 3 months follow-up (mean -87 µm versus -3 µm, respectively, p<0.001), 6 
months follow-up (-90 µm versus -3 µm, respectively, p<0.001) and 12 months 
follow-up (-113 µm versus -13 µm, respectively, p<0.001, Supplementary Table 2).  
 
Change in intraocular pressure 
Mean IOP was similar and remained relatively stable in both the study and fellow 
eyes prior to implant (15.7 mmHg and 16.0 mmHg at -12 months and 15.6 mmHg 
and 16.1 mmHg at implant, respectively, Figure 1). Post FAc implant in the study eye, 
mean IOP increased to 18.8mmHg at the end of the 12 month follow-up period. 
Conversely, mean IOP remained stable in the fellow eye (15.9 mmHg at +12 months, 
Figure 2). Change in IOP differed between the study eye and fellow eye at 3 months 
(mean 1.9 mmHg versus 0.55 mmHg, p=0.004), 6 months (2.4 mmHg versus 0.4 
mmHg, p<0.001) and 12 months (3.2 mmHg versus -0.2 mmHg, p<0.001) post index 
date (Supplementary Table 2).  
The number of study versus fellow eyes with an IOP of ≤21 mmHg was 12 (8%) 
versus 11 (7%) at baseline (N=156 pairs of eye, p=1.000), 26 (18%) versus 19 (13%) at 
3 months (N=147, p=0.167), 31 (20%) versus 12 (8%) at 6 months (N=154, p=0.001) 
and 39 (25%) versus 11 (7%) at 12 months post FAc implant (N=157, p<0.001). 
IOP-lowering medicine was initiated in more study eyes than fellow eyes between 0 
and 3 months (3% versus 1%), 3 and 6 months (7% versus 1%) and 6 and 12 months 
(11% versus 4%) post index date.  
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Discussion 
In the study cohort, visual acuity and CFT improved in the 12 months following the 
insertion of the FAc intravitreal implant when compared with the 12 months prior to 
implant. Conversely, there was a small but significant increase in IOP in the study eye 
in the 12 months post FAc implant. For the fellow eye, CFT and IOP remained 
relatively stable across the 12 month periods prior to and following FAc implant in 
the study eye. However, there was a small deterioration in visual acuity in the fellow 
eye post FAc implant. At the end of the 12 month follow-up period, statistically 
significant improvements in visual acuity and CFT were observed in study eyes 
treated with FAc intravitreal implant when compared with the fellow eye. However, 
during the same period, a small statistically significant increase in IOP was observed 
in study eyes only. More fellow eyes were treated with anti-VEGF therapies in the 12 
months post FAc implant when compared with study eyes. However, more study 
eyes than fellow eyes were treated with steroid therapy between 6 and 12 months 
post implant. The number of fellow eyes and study eyes receiving macular laser 
therapy post implant were similar. An important limitation of this study was the 
difference in visual acuity and CFT between study and fellow eyes prior to FAc 
implant. However, prior to implant, IOP was similar in study and fellow eyes, 
suggesting that the comparison between study and fellow eyes is reasonable for this 
outcome.  
To date, the largest randomised controlled trials investigating the effectiveness of 
FAc have been the FAME studies, where people with DMO previously treated with 
macular laser therapy were randomised to receive sham injection (n=185), low-dose 
FAc implant (n=375) and high dose FAc implant (n=393).12,13 Campochiaro and 
colleagues reported that 28.7% of people randomised to 0.2 µg/day FAc implant 
achieved a ≥15 letter improvement in ETDRS score after three years compared with 
18.9% of people randomised to sham injection (p=0.018).13 The 0.2 µg/day FAc 
group also received fewer off-protocol treatments for DMO (15.2% compared with 
33% for the sham group).13 In this study, where the fellow eye acted as a control, we 
found that a ≥15 letter improvement was observed in 18% of study eyes and 4% of 
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fellow eyes after 12 months follow-up (p<0.001). Here, some of the study eyes and 
fellow eyes also received other DMO treatments as part of their routine care. 
However, a higher number of fellow eyes received other treatments for DMO post 
FAc implant. However, unlike the people included in the FAME studies, whose DMO 
had previously only been managed with macular laser therapy, 82% of study eyes 
and 47% of fellow eyes in this study had previously been treated with anti-VEGF 
injections, and 43% of study eyes and 19% of fellow eyes had been previously 
treated with steroids (triamcinolone or dexamethasone). Compared with the FAME 
study, a higher proportion of study eyes and fellow eyes had a pseudophakic lens at 
baseline (89% of study eyes and 53% of fellow eyes in this study versus 34.6% of 
those randomised to sham and 37.3% of those eyes randomised to the 0.2 µg/day 
FAc implant in the FAME study). In addition, people in this study were generally 
older and there was a higher proportion of people with type 1 diabetes. In a pre-
specified subgroup analysis, Cunha-Vaz and colleagues reported that a higher 
percentage of people with chronic DMO gained a 15 letter improvement in visual 
acuity when compared with those with non-chronic DMO.23 Although the chronicity 
of DMO was not collected as part of the ICE-UK study, we undertook a subgroup 
analysis to determine the baseline characteristics of those people who went on to 
respond better to FAc implant (difference in mean change in visual acuity between 
study eye and fellow eye at 12 months ≤-0.12 LogMAR units). We found that people 
who responded better were in general younger, had worse vision in their study and 
fellow eye at baseline and were more likely to have been previously treated with at 
least one steroid injection in the study eye.  
The FAMOUS (Fluocinolone in Human Aqueous) RCT, where people were 
randomised to the 0.2 µg/day implant, reported a mean change in visual acuity of 
5.7 letters at 12 months.24 In a retrospective study carried out by Elaraoud and 
colleagues, an improvement in visual acuity and CFT was observed in 15 out of 22 
eyes treated with FAc intravitreal implant.25 The subjects included were similar to 
those included in the ICE-UK study in that all included eyes had a pseudophakic lens 
and the majority had been previously treated with multiple anti-VEGF and laser 
therapies.25 
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Unlike an RCT where people are randomised to FAc or sham injection, this study had 
a retrospective observational design whereby the untreated eye acted as a natural 
control that had been exposed to the same patient and disease factors. However, in 
70% of people, the FAc intravitreal implant was inserted into the worse-seeing eye. 
At baseline, CFT was greater in the study eye when compared with the fellow eye. 
Baseline vision is likely to dictate the improvement or worsening of vision observed 
in an eye and the difference in visual acuity at baseline between study and fellow 
eyes. In addition, more fellow eyes received anti-VEGF treatments in the 12 months 
post FAc implant. These limitations need to be taken into account when interpreting 
the comparisons between study and fellow eye.  
Five cataract operations were observed in study eyes over the follow-up period. 
However, the majority of people had a pseudophakic lens in the study eye at the 
time of implant (89%). In the FAME study, in those with no history of receiving a 
cataract operation, cataract surgery was reported in 75% of the 0.2 µg/day FAc 
group and 23% of the sham group after 24 months of follow-up and was the most 
commonly reported adverse event.12 At 36 months, these figures were 82% and 
51%, respectively.13 The percentage of eyes with a phakic lens at baseline was higher 
in the FAME study when compared with ICE-UK (11% versus 65%).12 More study eyes 
initiated IOP-lowering medication post index date. IOP-lowering surgery was carried 
out in one study eye and two fellow eyes within 12 months of implant. However, 
following insertion of the FAc intravitreal implant, there was a small but statistically 
significant increase in IOP in study eyes when compared with fellow eyes. 
Furthermore, a statistically significant higher percentage of study eyes had an IOP of 
≥21 mmHg when compared with fellow eyes. In the FAME study, all included 
individuals had no prior history of glaucoma.12 Laser trabeculoplasty and incisional 
IOP-lowering surgery were reported to have been carried out in 1.3% and 4.8% of 
the 0.2 µg/day FAc implant group and 0% and 0.5% of the sham group, 
respectively.13  
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Strengths and limitations 
The general study limitations have largely been discussed previously.20 The 
comparison of study and fellow eyes had statistical limitations.  The decision to treat 
one eye with FAc instead of or before the fellow eye is based on clinical judgment 
and is not a random event. The study eye often had poorer visual acuity and CFT at 
baseline compared with the fellow eye. This could have led to confounding by 
severity. Conversely, worse characteristics at baseline could have potentially led to 
improved outcomes and therefore favoured the study eye. The FAc implant is 
licensed for the treatment of DMO considered insufficiently responsive to available 
therapies. Therefore, when the FAc implant was inserted into the worse-seeing eye, 
the better-seeing eye could still have been responsive to other DMO treatments. 
However, little improvement was observed in the fellow eye over the 12 months 
before and after index date, and only 18%, 20% and 24% of fellow eyes received 
anti-VEGF therapy at 0 to 3 months, 3 to 6 months and 6 to 12 months post index 
date. The UK NICE guidelines recommend that the FAc intravitreal implant be 
prescribed in eyes with a pseudophakic lens18 and this may have also influenced the 
decision as to which eye to treat with FAc. For 37% of patients who received an FAc 
implant in their worse-seeing eye, the fellow eye was phakic at the time of implant. 
For those patients, whose visual acuity was the same or better in the study eye, 31% 
had a phakic lens in their fellow eye. Collection parameters included DMO type for 
each eye, but a status of no DMO could not be recorded. Unilateral cases of DMO 
were reported separately for three study subjects. The level of misclassification of 
the unilateral and bilateral DMO status is unknown, although 26% patients had no 
history of receiving any treatment for DMO (laser, intravitreal steroids or anti-VEGF 
therapy) prior to index date (compared with 3% of study eyes). 
Several types of OCT machine were used to measure retinal thickness across the 13 
participating ophthalmology centres, and this has been discussed in detail 
elsewhere.26 Retinal thickness measurements have been shown to vary depending 
on machine type, possibly due to variation in the retinal segmentation algorithms 
used by different OCT machines.27 However, the same OCT machine type was used 
to measure retinal thickness in the left and right eye during the same visit. 
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Due to the low level of systemic absorption, the effect of the FAc implant on the 
fellow eye is thought to be low. However, bevacizumab has been reported to 
significantly reduce the level of VEGF in the blood plasma for up to 28 days post 
injection in people with DMO and age-related macular degeneration.28,29 
Furthermore, studies have shown that anti-VEGF therapy administered unilaterally 
can have beneficial effects in the contralateral eye of people with bilateral DMO,30 
age-related diabetic macular degeneration,31 proliferative diabetic retinopathy,32 
uveitis-related cystoid macular oedema.33 The potential crossover effect of anti-
VEGF therapy on the contralateral (study or fellow) eye is a limitation of the study 
design. 
 
Conclusion 
At the end of the 12 months follow-up period, a statistically significant improvement 
in visual acuity and CFT and a small but significant increase in intraocular pressure 
were observed in study eyes treated with FAc intravitreal implant when compared 
with the fellow eye. Differences in baseline visual acuity and CFT between study and 
fellow eyes were a limitation of this study. However, considering the study and 
fellow eyes independently, trends in visual acuity and CFT over the 12 month periods 
before and after FAc implant highlight the benefit of FAc intravitreal implant in the 
often poorer study eye. Over the same period, little or no improvement in these 
outcomes was observed in fellow eyes.  
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Tables and figures 
Table 1 | Baseline characteristics 
Parameter Study eye Fellow eye p-value 
Patient characteristics 
     
Subjects, n 208 
 
208 
  
Age last clinic visit, mean (SD)a 68.1 (10.7) 68.1 (10.7) 
 
Males, n (%) 128 (62%) 128 (62%) 
 
Type 1 diabetes, n (%) 32 (15%) 32 (15%)  
Oral hypoglycaemic agents 0 (0%) 0 (0%)  
Insulin 28 (88%) 28 (88%)  
Insulin plus oral antihyperglycaemic agents 4 (13%) 4 (13%)  
Type 2 diabetes, n (%) 176 (85%) 176 (85%) 
 
Oral antihyperglycaemic agents 76 (43%) 76 (43%) 
 
Insulin 43 (24%) 43 (24%) 
 
Insulin plus oral antihyperglycaemic 57 (32%) 57 (32%) 
 
Number of years with diabetes, median (IQR)a 18 (11-27) 18 (11-27) 
 
      
Eye characteristics 
     
Pseudophakic lens status, n (%)d 185 (89%) 111 (53%) <0.001 
Visual acuity, LogMAR unitsbc 
     
n (%) 196 (94%) 196 (94%) 
 
Median (IQR) 0.69 (0.49-1) 0.4 (0.19-0.8) <0.001 
Visual acuity, ETDRS lettersbc      
n (%) 196 (94%) 196 (94%)  
Median (IQR) 50 (35–60.5) 65 (45–75)  
Visual acuity compared with other eye, n (%)bc 
     
Same 20 (10%) 20 (10%) 
 
Better 39 (20%) 137 (70%) 
 
Worse 137 (70%) 39 (20%) 
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Centre subfield thickness, mbc 
     
n (%) 172 (83%) 172 (83%) 
 
Median (IQR) 445 (353-575) 325 (273-401) <0.001 
Central foveal thickness, mbcd 
     
n (%) 160 (77%) 160 (77%) 
 
mean (SD) 483 (189) 371 (176) <0.001 
IOP, mmHgbc 
     
n (%) 156 (75%) 156 (75%) 
 
Median (IQR), mmHg 15.0 (13-18) 15.0 (13.75-18) 0.236 
Prior macular laser treatments 
     
n (%) 127 (61%) 115 (55%) 
 
Median (IQR) 1 (0-2.5) 1 (0-2) 0.028 
Prior anti–VEGF injections 
     
n (%) 170 (82%) 98 (47%) 
 
Median (IQR) 4 (2-7) 0 (0-4.5) <0.001 
Prior ranibizumab injections 
     
n (%) 144 (69%) 78 (38%) 
 
Median (IQR) 3 (0-6) 0 (0-3) <0.001 
Prior aflibercept injections 
     
n (%) 1 (0%) 0 (0%) 
 
Median (IQR) 0 (0-0) 0 (0-0) 0.317 
Prior bevacizumab injections 
     
n (%) 63 (30%) 37 (18%) 
 
Median (IQR) 0 (0-2) 0 (0-0) <0.001 
Prior steroid injections, 
     
n (%) 89 (43%) 39 (19%) 
 
Median (IQR) 0 (0-1) 0 (0-0) <0.001 
Prior dexamethasone injections 
     
n (%) 14 (7%) 5 (2%) 
 
Median (IQR) 0 (0-0) 0 (0-0) 0.015 
Prior triamcinolone injections 
     
n (%) 79 (38%) 34 (16%) 
 
Median (IQR) 0 (0-1) 0 (0-0) <0.001 
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IOP-lowering medication, n (%) 41 (20%) 34 (16%) 0.143 
Prostaglandin analogues, n (%) 26 (13%) 15 (7%) 0.007 
Beta blockers, n (%) 14 (7%) 14 (7%) 1.000 
Alpha agonists, n (%) 5 (2%) 6 (3%) 1.000 
Carbonic anhydrase inhibitors, n (%) 11 (5%) 9 (4%) 0.754 
Other, n (%) 7 (3%) 8 (4%) 1.000 
SD = standard deviation, IQR = interquartile range, LogMAR = logarithm of the minimum angle of resolution, ETDRS = Early treatment diabetic retinopathy study, IOP = 
intraocular pressure, VEGF = vascular endothelial growth factor. 
a These are approximate estimates as it was not possible to determine the exact date on which these parameters were recorded in the dataset. 
b Nearest value recorded ≤index date providing that it occurs no more than 365 days prior to the index date. 
c Pairs of values included only. Individuals with a value missing for study and/or fellow eye are not included. 
d Central foveal thickness was measured using Heidelberg SPECTRALIS in 103 patients, Topcon 3D OCT in 55 patients and Topcon 3D OCT-1000 in 2 patients.
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Supplementary Table 1 | Baseline characteristics by subgroup based on difference in change in mean visual acuity at 12 months 
between study eye and fellow eye (change in visual acuity for study eye minus change in visual acuity for fellow eye) 
 
Difference in change in visual acuity ≥-0.13 Difference in change in visual acuity ≤-0.13  
Study eye Fellow eye Study eye Fellow eye 
Subjects, n 96 
 
96 
 
62 
 
62 
 
Age last clinic visit, mean (SD)a 70.1 (9.2) 70.1 (9.2) 67 (11) 67 (11) 
Males, n (%) 64 (67%) 64 (67%) 39 (63%) 39 (63%) 
Type 2 diabetes, n (%) 82 (85%) 82 (85%) 56 (90%) 56 (90%) 
Tablets 28 (34%) 28 (34%) 32 (57%) 32 (57%) 
Insulin 22 (27%) 22 (27%) 9 (16%) 9 (16%) 
Insulin plus tablets 32 (39%) 32 (39%) 15 (27%) 15 (27%) 
Type 1 diabetes, n (%) 14 (15%) 14 (15%) 6 (10%) 6 (10%) 
Tablets 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Insulin 13 (93%) 13 (93%) 6 (100%) 6 (100%) 
Insulin plus tablets 1 (7%) 1 (7%) 0 (0%) 0 (0%) 
Number of years with diabetes, median 
(IQR)a 
18 (10.8–28) 18 (10.8–28) 16 (10–22.8) 16 (10–22.8) 
Pseudophakic lens status, n (%) 84 (88%) 57 (59%) 56 (90%) 24 (39%) 
Visual acuity, median (IQR), LogMAR scalebc 0.6 (0.41–0.8) 0.31 (0.19–0.71) 0.8 (0.5–1.09) 0.395 (0.19–0.7) 
Central subfield thickness, mbc 
        
n (%) 85 (89%) 85 (89%) 53 (85%) 53 (85%) 
Median (IQR) 436 (336–532) 316 (268–372) 453 (385–561) 326 (283–401) 
Central foveal thickness, mbc 
        
n (%) 77 (80%) 77 (80%) 49 (79%) 49 (79%) 
median (IQR) 457 (360–587) 332 (258–387) 473 (374–597) 308 (242–399) 
IOP, mmHgbc 
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n (%) 78 (81%) 78 (81%) 45 (73%) 45 (73%) 
Median (IQR), mmHg 15 (13–17) 15 (13–17) 16 (14–18) 16 (14–18) 
Prior macular laser treatments 
        
n (%) 54 (56%) 48 (50%) 39 (63%) 35 (56%) 
Median (IQR) 1 (0–2) 0.5 (0–2) 1 (0–3) 1 (0–2) 
Prior anti–VEGF injections 
        
n (%) 79 (82%) 39 (41%) 50 (81%) 27 (44%) 
Median (IQR) 4 (2–7) 0 (0–3.5) 5 (1–7) 0 (0–3) 
Prior ranibizumab injections 
        
n (%) 70 (73%) 32 (33%) 43 (69%) 19 (31%) 
Median (IQR) 3 (0–6) 0 (0–3) 3 (0–6) 0 (0–2) 
Prior aflibercept injections 
        
n (%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 
Median (IQR) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 
Prior bevacizumab injections 
        
n (%) 19 (20%) 11 (11%) 19 (31%) 9 (15%) 
Median (IQR) 0 (0–0) 0 (0–0) 0 (0–3) 0 (0–0) 
Prior steroid injections 
        
n (%) 37 (39%) 14 (15%) 30 (48%) 8 (13%) 
Median (IQR) 0 (0–1) 0 (0–0) 0 (0–1) 0 (0–0) 
Prior dexamethasone injections 
        
n (%) 6 (6%) 1 (1%) 5 (8%) 1 (2%) 
Median (IQR) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 
Prior triamcinolone injections 
        
n (%) 32 (33%) 13 (14%) 28 (45%) 7 (11%) 
Median (IQR) 0 (0–1) 0 (0–0) 0 (0–1) 0 (0–0) 
IOP-lowering medication, n (%) 19 (20%) 16 (17%) 15 (24%) 11 (18%) 
Prostaglandin analogues, n (%) 13 (14%) 7 (7%) 9 (15%) 6 (10%) 
Beta blockers, n (%) 4 (4%) 3 (3%) 6 (10%) 6 (10%) 
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Alpha agonists, n (%) 3 (3%) 4 (4%) 2 (3%) 2 (3%) 
Carbonic anhydrase inhibitors, n (%) 3 (3%) 4 (4%) 5 (8%) 4 (6%) 
Other, n (%) 5 (5%) 5 (5%) 1 (2%) 1 (2%) 
SD = standard deviation, IQR = interquartile range, LogMAR = logarithm of the minimum angle of resolution, ETDRS = Early treatment diabetic retinopathy study, IOP = 
intraocular pressure, VEGF = vascular endothelial growth factor. 
a These are approximate estimates as it was not possible to determine the exact date on which these parameters were recorded in the dataset. 
b Nearest value recorded ≤index date providing that it occurs no more than 365 days prior to the index date. 
c Pairs of values included only. Individuals with a value missing for study and/or fellow eye are not included.
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Table 2 | Number of eyes prescribed therapies before and after treatment 
with fluocinolone intravitreal implant  
Parameter Study eye Fellow eye  
N (%) N (%) 
Subjects, n 208 
 
208 
 
Macular laser treatments 
    
Prior to FAc implant 127 (61%) 115 (55%) 
0 to 3 months 3 (2%) 3 (2%) 
3 to 6 months 5 (3%) 4 (2%) 
6 to 12 months 9 (5%) 6 (4%) 
Anti-VEGF injections 
    
Prior to FAc implant 170 (82%) 98 (47%) 
0 to 3 months 9 (5%) 35 (18%) 
3 to 6 months 16 (9%) 37 (20%) 
6 to 12 months 31 (18%) 41 (24%) 
Steroid injections 
    
Prior to FAc implant 89 (43%) 39 (19%) 
0 to 3 months 3 (2%) 2 (1%) 
3 to 6 months 2 (1%) 1 (0.6%) 
6 to 12 months 8 (5%) 2 (1%) 
IOP-lowering surgery 
    
Prior to FAc implant 0 (0%) 1 (0.5%) 
0 to 3 months 0 (0%) 0 (0%) 
3 to 6 months 0 (0%) 1 (0.6%) 
6 to 12 months 1 (0.6%) 1 (0.6%) 
Vitrectomy 
    
Prior to FAc implant 45 (22%) 16 (8%) 
0 to 3 months 1 (0.5%) 0 (0%) 
3 to 6 months 1 (0.6%) 1 (0.6%) 
6 to 12 months 2 (1%) 1 (0.6%) 
Incident cataract operation 
    
Prior to FAc implant 185 (89%) 111 (53%) 
0 to 3 months 15a (68%) 10 (11%) 
3 to 6 months 1 (14%) 3 (4%) 
6 to 12 months 0 (0%) 4 (5%) 
Newly prescribed IOP-lowering 
therapies 
    
Prior to FAc implant 41 (20%) 34 (16%) 
0 to 3 months 5 (3%) 1 (0.6%) 
3 to 6 months 9 (7%) 1 (0.7%) 
6 to 12 months 13 (11%) 5 (4%) 
a Includes 11 cataract operations carried out on the day of FAc implant.b Percentages post implant are 
calculated based on the number of phakic eyes remaining.  
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Supplementary Table 2 | Change in visual acuity, central subfield and central foveal thickness and IOP post implant in study eye 
 
N Change in study eye  Change in fellow eye p-value   
Mean (SD) Median (IQR) Mean (SD) Median (IQR) 
 
Change in visual 
acuity, LogMAR units 
   
  
  
  
 
At 3 months 168 -0.08 (0.35) 0.00 (-0.20–0.00) -0.02 (0.3) 0.00 (-0.10–0.04) 0.009 
At 6 months 165 -0.11 (0.37) -0.06 (-0.20–0.00) 0.03 (0.32) 0.00 (-0.10–0.10) <0.001 
At 12 months 158 -0.09 (0.38) -0.02 (-0.20–0.10) 0.04 (0.29) 0.00 (-0.07–0.12) <0.001     
  
  
  
 
Change in central 
foveal thickness, µm 
   
  
  
  
 
At 3 monthsa 118 -87 (189) -66 (-188–5.0) -2.9 (122) -3.5 (-49–18) <0.001 
At 6 monthsa 118 -90 (218) -75 (-208–9.0) -2.9 (123) -5.5 (-55–26) <0.001 
At 12 monthsb 114 -113 (216) -102 (-219–9.0) -13.0 (121) -10 (-58–21) <0.001     
  
  
  
 
Change in IOP, 
mmHg 
   
  
  
  
 
At 3 months 116 1.9 (6.4) 1.0 (-1.5–4.0) 0.6 (5.3) 0.0 (-2.0–3.0) <0.001 
At 6 months 121 2.4 (6.8) 1.0 (-1–5.0) 0.4 (5.2) 0.0 (-2.0–3.0) <0.001 
At 12 months 120 3.2 (7.3) 2.0 (-1.4–6.0) -0.2 (4.7) 0.0 (-2.5–3.0) <0.001 
Pairs of eyes with complete data included only. Last observation carried forward was used to impute missing values in two stages, prior to (up to a maximum of 365 days) 
and after index date. Eyes with missing visual acuity score (i.e. no visual acuity recorded between index date and the study time point) were excluded.  
a Central foveal thickness was measured on different OCT machine types in 5% of eyes. 
b Central foveal thickness was measured on different OCT machine types in 6% of eyes.  
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Figure 1 | Mean visual acuity, central subfield and central foveal thickness and IOP for study and fellow eyes 
a) Visual acuity b) IOP 
    
c) Central foveal thickness  
  
 
Missing values were imputed using linear interpolation. Last observation carried forward was then used following the last recorded value within the 365 day follow-up period. Last 
observation carried forward was used in the year prior to index date in order to impute missing values at the time of implant in the study eye. 
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Figure 2 | Mean change in visual acuity, central subfield and central foveal thickness and IOP post index date for study and fellow eyes 
a) Change in visual acuity b) Change in IOP 
    
c) Change in central foveal thickness  
   
 
Missing values were imputed using linear interpolation. Last observation carried forward was then used following the last recorded value within the 365 day follow-up period. Last 
observation carried forward was used in the year before index date in order to impute missing values at the time of implant in the study eye. 
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Figure 3 | Percentage of study and fellow eyes achieving a) ≥5, ≥10 and ≥15 letter 
improvement in ETDRS score and b) ≥5, ≥10 and ≥15 letter worsening in ETDRS 
score 
a) 
 
b) 
 
 
 * Indicates significance at the <0.05 level and **indicates significance at the <0.001 level.
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Table 3 | Results from the generalised linear mixed model 
Change in visual acuity 
(ETDRS letter score) 
Parameter Coefficient Exponential of the coefficient p-value   
Estimate Lower CI Upper CI 
 
At 3 months 
      
≥5 letter improvement Age -0.008 0.992 0.964 1.02 0.567  
Baseline visual acuity 0.572 1.771 0.987 3.18 0.055  
Female 0.177 1.193 0.661 2.154 0.556  
Male (reference) 0 
    
 
Insulin treatment -0.037 0.963 0.501 1.852 0.91  
No insulin treatment (reference) 0 
    
 
Intercept -0.304 0.738 0.095 5.74 0.771  
Pseudophakic lens 0.07 1.073 0.504 2.282 0.855  
Phakic lens (reference) 0 
    
 
Diabetes duration -0.013 0.987 0.962 1.013 0.317  
Number of prior anti-VEGF injections 0.003 1.003 0.931 1.082 0.93  
Prior treatment for IOP 0.01 1.01 0.516 1.976 0.976  
No prior treatment for IOP (reference) 0 
    
 
Number of prior laser therapies -0.014 0.986 0.876 1.11 0.814  
Number of prior steroid injectionsa -0.003 0.997 0.782 1.271 0.978 
 
Prior vitrectomy 0.142 1.153 0.537 2.478 0.714  
No prior vitrectomy (reference) 0 
    
 
Study eye 0.737 2.09 1.127 3.877 0.019  
Fellow eye (reference) 0 
    
≤5 letter worsening Age 0.022 1.023 0.987 1.06 0.221  
Baseline visual acuity 0.063 1.065 0.495 2.293 0.871  
Female 0.497 1.644 0.825 3.274 0.157  
Male (reference) 0 
    
 
Insulin treatment 0.102 1.108 0.514 2.389 0.793  
No insulin treatment (reference) 0 
    
 
Intercept -2.872 0.057 0.004 0.755 0.03 
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Pseudophakic lens 0.522 1.685 0.716 3.962 0.231  
Phakic lens (reference) 0 
    
 
Diabetes duration -0.008 0.992 0.963 1.022 0.594  
Number of prior anti-VEGF injections 0.066 1.069 0.978 1.167 0.141  
Prior treatment for IOP -0.406 0.667 0.271 1.639 0.376  
No prior treatment for IOP (reference) 0 
    
 
Number of prior laser therapies 0.041 1.041 0.899 1.206 0.587  
Number of prior steroid injectionsa -0.378 0.685 0.439 1.069 0.095 
 
Prior vitrectomy 0.03 1.03 0.389 2.725 0.952  
No prior vitrectomy (reference) 0 
    
 
Study eye -0.08 0.923 0.451 1.892 0.827  
Fellow eye (reference) 0 
    
At 6 months 
      
≥5 letter improvement Age 0.003 1.003 0.974 1.033 0.854  
Baseline visual acuity 0.725 2.064 1.107 3.848 0.023  
Female 0.51 1.665 0.917 3.023 0.094  
Male (reference) 0 
    
 
Insulin treatment -0.176 0.839 0.433 1.627 0.602  
No insulin treatment (reference) 0 
    
 
Intercept -1.203 0.3 0.035 2.582 0.272  
Pseudophakic lens -0.139 0.871 0.411 1.845 0.717  
Phakic lens (reference) 0 
    
 
Diabetes duration 0.005 1.005 0.978 1.032 0.716  
Number of prior anti-VEGF injections 0.025 1.025 0.951 1.106 0.512  
Prior treatment for IOP 0.059 1.061 0.547 2.059 0.861  
No prior treatment for IOP (reference) 0 
    
 
Number of prior laser therapies 0.03 1.031 0.916 1.161 0.614  
Number of prior steroid injectionsa -0.03 0.97 0.759 1.241 0.811  
Prior vitrectomy 0.184 1.202 0.554 2.607 0.641  
No prior vitrectomy (reference) 0 
    
 
Study eye 0.516 1.676 0.882 3.185 0.114 
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Fellow eye (reference) 0 
    
≤5 letter worsening Age 0.008 1.008 0.974 1.042 0.655  
Baseline visual acuity -0.075 0.928 0.428 2.014 0.85  
Female 0.906 2.475 1.276 4.801 0.008  
Male (reference) 0 
    
 
Insulin treatment -0.378 0.685 0.324 1.45 0.322  
No insulin treatment (reference) 0 
    
 
Intercept -1.115 0.328 0.028 3.832 0.373  
Pseudophakic lens 0.024 1.024 0.462 2.271 0.954  
Phakic lens (reference) 0 
    
 
Diabetes duration -0.004 0.996 0.967 1.027 0.813  
Number of prior anti-VEGF injections 0 1 0.916 1.092 0.999  
Prior treatment for IOP -0.161 0.852 0.385 1.884 0.691  
No prior treatment for IOP (reference) 0 
    
 
Number of prior laser therapies 0.04 1.041 0.905 1.197 0.57  
Number of prior steroid injectionsa -0.148 0.863 0.612 1.216 0.397 
 
Prior vitrectomy 0.165 1.179 0.471 2.956 0.724  
No prior vitrectomy (reference) 0 
    
 
Study eye 0.026 1.026 0.5 2.109 0.943  
Fellow eye (reference) 0 
    
At 12 months 
      
≥5 letter improvement Age -0.015 0.985 0.952 1.019 0.388  
Baseline visual acuity 0.426 1.531 0.808 2.901 0.19  
Female 0.507 1.661 0.847 3.256 0.139  
Male (reference) 0 
    
 
Insulin treatment -0.017 0.983 0.464 2.082 0.965  
No insulin treatment (reference) 0 
    
 
Intercept -0.476 0.622 0.05 7.676 0.71  
Pseudophakic lens 0.595 1.813 0.776 4.238 0.169  
Phakic lens (reference) 0 
    
 
Diabetes duration 0 1 0.97 1.03 0.999  
Number of prior anti-VEGF injections 0.032 1.033 0.956 1.115 0.411 
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Prior treatment for IOP -0.141 0.869 0.436 1.73 0.687  
No prior treatment for IOP (reference) 0 
    
 
Number of prior laser therapies -0.038 0.962 0.845 1.096 0.561  
Number of prior steroid injectionsa 0.019 1.019 0.793 1.31 0.88 
 
Prior vitrectomy 0.07 1.073 0.438 2.629 0.878  
No prior vitrectomy (reference) 0 
    
 
Study eye 0.606 1.832 0.921 3.647 0.084  
Fellow eye (reference) 0 
    
≤5 letter worsening Age -0.01 0.99 0.959 1.022 0.528  
Baseline visual acuity -1.095 0.334 0.143 0.78 0.011  
Female 0.79 2.202 1.156 4.194 0.016  
Male (reference) 0 
    
 
Insulin treatment -0.76 0.468 0.222 0.984 0.045  
No insulin treatment (reference) 0 
    
 
Intercept 0.561 1.752 0.169 18.209 0.638  
Pseudophakic lens 0.319 1.376 0.632 2.994 0.42  
Phakic lens (reference) 0 
    
 
Diabetes duration -0.005 0.995 0.967 1.024 0.736  
Number of prior anti-VEGF injections 0.058 1.06 0.982 1.144 0.136  
Prior treatment for IOP -0.354 0.702 0.346 1.426 0.327  
No prior treatment for IOP (reference) 0 
    
 
Number of prior laser therapies -0.048 0.953 0.835 1.087 0.471  
Number of prior steroid injectionsa -0.008 0.992 0.744 1.322 0.955 
 
Prior vitrectomy 0.927 2.527 1.069 5.971 0.035  
No prior vitrectomy (reference) 0 
    
 
Study eye 0.114 1.12 0.546 2.299 0.756  
Fellow eye (reference) 0 
    
 
